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Abstract 
Fibrosis is the leading cause of organ dysfunction in diseases such as systemic sclerosis, liver 
cirrhosis, cardiac fibrosis, progressive kidney disease, and idiopathic pulmonary fibrosis. The 
hallmark of fibrosis is tissue remodeling with excess deposition of extracellular matrix components, 
predominantly collagens. Different cell types, cytokines, growth factors, and enzymes interact in 
complex pathogenic networks with myofibroblasts playing a pivotal role. MicroRNAs are small 
non-coding RNAs acting as negative regulators of gene expression at the post-transcriptional level. 
MicroRNAs have been associated with many basic cellular processes as well as with a wide 
spectrum of diseases, most notably cancer. This review provides a comprehensive overview of 
microRNAs regulating profibrotic pathways and extracellular matrix synthesis. The potential of 
miRNA for targeted therapeutic approaches in fibrotic disorders is also discussed. 
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Introduction 
Fibrosis is a leading cause of organ dysfunction in diseases, either as the outcome of an 
uncontrolled reaction to chronic tissue injury, or as the primary disease itself in predisposed 
individuals [1-4] (Table 1). Independently from the initiating trigger and the tissue-specific 
response, the hallmark of fibrosis is excess deposition of extracellular matrix (ECM) components, 
predominantly collagens and associated glycoproteins. Accumulating ECM replaces functional 
tissue, and disrupts organ architecture [1]. Different cell types, cytokines, growth factors, and 
enzymes are orchestrated together in complex pathogenic networks, converging on the activation 
and/or recruitment of fibroblasts and their differentiation into myofibroblasts, which are α-smooth 
muscle actin (α-SMA) enriched cells overproducing ECM [5-7]. It is currently believed that along 
with these cellular key players, a number of regulatory factors also have substantial effects on 
fibrosis and may be responsible for inter-organ variability of fibrotic manifestations [8].  
In this scenario, microRNAs (miRNAs) may play the role of conductors in the pathogenesis 
of fibrosis [9]. MiRNAs are small, non-coding RNAs with a strictly regulated biogenesis. This is 
combined with an extremely flexible and sophisticated regulatory function, allowing simultaneous 
targeting of multiple proteins involved in different crucial biological pathways of specific cell types 
and tissues [10]. Consequently, miRNAs have been associated with many basic cellular processes 
such as cell death, proliferation and differentiation. On the other hand, miRNA dysregulation has 
also been linked to a wide spectrum of diseases, most notably cancer [11]. 
A number of recent reviews have addressed the role of miRNA in fibrosis with a focus on 
organ-specific miRNA alteration [12-15]. Here we paid special attention to miRNA alterations 
common to different fibrotic disorders such as systemic sclerosis (SSc) [16], liver cirrhosis (LC) 
[17], cardiac fibrosis (CF) [18, 19], chronic kidney disease (CKD) [20], and idiopathic pulmonary 
fibrosis (IPF) [21]. miRNAs directly regulating ECM synthesis and miRNAs regulating TGF-
β/CTGF signaling as a key profibrotic pathway were considered for this review.  
4 
 
MicroRNA biogenesis and function 
miRNAs are a class of small, evolutionarily conserved, non-coding RNAs, which repress the 
expression of protein coding genes at the post-transcriptional level via a partially complementary 
binding to the 3’ untranslated region (UTR) of target mRNAs [22, for comprehensive review]. To 
date, 1426 miRNA encoding sequences have been identified in the human genome and more than 
half of them have been experimentally validated 
(ftp://mirbase.org/pub/mirbase/CURRENT/genomes/hsa.gff) [23].  Most miRNA genes are located 
in introns, exons and UTRs of protein coding genes. Approximately one quarter of miRNAs are 
encoded in inter-genic regions, and display an independent transcription unit, whereas intronic and 
exonic miRNAs are usually co-transcribed and co-expressed with the host gene [22] . In addition, a 
half of known miRNAs are encoded by polycistronic units, generating multiple miRNAs, often 
related in their structure and function [22, 24].  
miRNAs are transcribed as long polyadenylated RNAs, pri-miRNAs, which contain one or 
more mature miRNA sequences. Pri-miRNAs are cut by the endonuclease Drosha and its co-factor 
DiGeorge syndrome critical region 8 (DGCR8), originating intermediate 60-100 nucleotide hairpin 
structures called pre-miRNAs [22]. Pre-miRNAs are transported to the cytoplasm by exportin 5 and 
further processed by another endonuclease, Dicer, releasing functionally active, mature miRNAs 
with a lengths of ≈ 22 nucleotides. Each mature miRNA is then incorporated into the RNA-induced 
silencing complex (RISC), which allows the recognition of target mRNA and the formation of a 
miRNA:mRNA duplex [22]. The base pairing of the duplex is mediated by a distinct seed region at 
nucleotides 2-8 of the miRNA, and alters mRNA stability or affects protein translation [25]. 
Translational repression and also target mRNA destabilization predominat in humans, although in 
rare cases miRNAs can switch their negative regulatory function towards gene activation by 
promoting mRNA translation [26].  
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The “imperfect” miRNA-mRNA binding is the basis for an extremely flexible regulatory 
system, as one miRNA can regulate hundreds of genes, and one gene containing multiple partially 
complementary binding sites in its 3’UTR can be regulated by multiple miRNAs [24]. In addition, 
this flexibility in miRNA-mRNA interaction is further expanded by a number of variables: miRNA 
binding site accessibility, RNA secondary structure, position of the binding site in the 3’UTR and 
its distance from the stop codon, and reciprocal interference between different miRNAs and RNA 
binding proteins sharing the same target [27]. As a consequence, miRNA activity depicts a gray 
scale rather than a black-or-white regulatory scenario [27, 28]. This aspect is particularly relevant 
for the regulation of multistep biological processes such as signaling pathways: while the effect of a 
given miRNA on the overall activity of the pathway can be potent, this often results from the sum 
of subtle modulations on multiple constituents of the same pathway rather than from strong effects 
on a single molecule [28]. Comprehensive in silico analysis of miRNA targets is provided at the 
miRGen database (http://www.diana.pcbi.upenn.edu/miRGen.html), which merges the results of 
multiple miRNA prediction databases, such as DIANA microT, miRanda (microrna.org), miRanda 
(miRBase), PicTar (4-way and 5-way), and TargetScanS [29]. 
Despite this versatile regulatory activity, the expression of miRNA genes is tightly 
controlled, and specific cell types often display a certain miRNA profile [22]. Regulation of miRNA 
expression at both the transcriptional and post-transcriptional level is still poorly understood. 
However, multiple mechanisms may play a role. At the transcriptional level, miRNAs can control 
their own expression establishing either positive or negative regulatory loops via an indirect 
regulation of  transcriptional activators or repressors [30]. Epigenetic modifications such as DNA 
and histone methylation and histone deacetylation also participate in the modulation of miRNA 
transcription [31, 32]. At the post-transcriptional level, factors influencing the activity of the 
endonucleases Drosha and Dicer affect selective miRNA cluster maturation [33, 34]. In addition, 
some pseudogene mRNAs can act as miRNA decoy through a 3’UTR, which is highly homologous 
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to the one of the related protein-coding mRNA, thus modulating cell levels of “free” miRNA [35]. 
Finally, exosome-mediated cell-cell exchange of RNA has also been described as a determinant of 
cellular miRNA profile [36]. 
Figure 1 gives an overview of miRNA biogenesis and function. 
SSc: a model for fibrotic diseases? 
Despite fibrotic disorders include a large number of primary and secondary entities with 
distinct features, major extracellular mediators of fibrosis and related signaling pathways are 
nevertheless common to most of them. This includes cytokines, chemokines, growth factors, and 
other small secreted signaling proteins (Table 2) [2].  
SSc is a systemic fibrotic disease of unknown origin characterized by the presence of three 
main pathophysiological pathways in each target organ/system: vascular injury, immune system 
activation, and interstitial fibrosis [37]. Thus, we propose SSc as a paradigm of fibrotic disorders, 
based on the following observations: i) fibrosis in SSc can virtually affect all organs/systems, 
although the disease displays apparent clinical involvement at preferential sites (skin, lungs, heart, 
kidneys, gastrointestinal tract, muscles); ii) initial factors triggering pro-fibrotic pathways in other 
fibrotic diseases are also discussed in SSc and SSc-like diseases including infections, autoimmune 
phenomena, and exposure to toxics or radiations [38-41]; iii) consistent evidence for the activation 
of major pro-fibrotic pathways common to most fibrotic diseases has been reported in SSc, 
including transforming growth factor-β (TGF-β) pathways, the platelet-derived growth factor 
(PDGF) pathway, and, most recently, the canonical Wnt-β-catenin pathway and the serotonin 
pathway [42-46].  
 
Overview of pro- and anti-fibrotic microRNAs 
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According to the current literature, ≈ 40 miRNAs have been linked to fibrosis in various 
organs and disease settings (Table 3). In general, the miRNA profile is specific for a given cell-
type, and even more specific in relation to the developmental and functional organ status [22]. This 
might explain, why many miRNAs with pro- or anti-fibrotic properties were found to be 
dysregulated in specific organs and specific fibrotic diseases [48, 49, 52, 55, , 59, 64, 68-71, 76-82]. 
On the other hand, some miRNAs have been found to be abnormally expressed in more than one 
fibrotic disorder [47, 50, 51, 53, 54, 56-58, 60-63, 65-67, 72-75]. Predicted targets of approximately 
half of miRNAs involved in fibrosis have been validated by reporter gene assay [84]. Most of these 
miRNAs directly induce or protect from fibrosis by targeting TGF-β canonical and non-canonical 
pathways [62, 65-67, 69, 82], connective tissue growth factor (CTGF) [51, 52, 58, 83], ECM 
structural proteins or enzymes involved in ECM remodeling [47, 72-75, 79, 81]. Another set of 
miRNAs indirectly regulates fibrogenesis by affecting epithelial-to-mesenchymal transition (EMT) 
[48, 50, 51, 56, 59, 63, 68, 80], or by inducing proliferation and resistance to apoptosis in 
myofibroblasts [51, 53-55, 71, 76, 78] (Table 3).   
 
MicroRNA regulation of TGF-β/CTGF signaling 
TGF-β is a central mediator of fibrosis [1] and it is ubiquitously expressed in tissues [85]. 
TGF-β also induces expression of CTGF, and CTGF can in turn enhance TGF-β signaling, along 
with a number of other pro-fibrotic factors including vascular endothelial growth factor (VEGF), 
endothelin-1 (ET), insulin-like growth factor-1 (IGF-1), integrins, and Wnts [86]. Therefore, 
miRNA regulation of TGF-β and CTGF signaling is of paramount interest. Up-to-date, 10 miRNAs 
showed consistent experimental evidence of being TGF-β/CTGF signaling regulators. Six of them 
were dysregulated in more than one fibrotic disorder (see Table 3).  
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miR-17-92 cluster. MiR-17-92 is a proto-oncogenic cluster (also called oncomir-1) 
consisting of six miRNAs. Very recently, miR-18a and miR-19a/b from this cluster have been 
shown to regulate CTGF and thrombospondin-1 (TSP-1) in the context of liver and cardiac fibrosis 
[58, 83]. In a previous report, CTGF and TSP-1 were validated as direct miR-18a/miR-19a/b targets 
in cancer [87]. Kodama et al. [58] reported down-regulation of the miR-17-92 cluster in liver 
fibrosis in a p53-dependent manner and an associated up-regulation of CTGF. Similarly, van Almen 
et al. [83] showed down-regulation of the miR-17-92 cluster and spontaneous upregulation of 
CTGF and TSP-1 in a mouse model of age-related heart failure, which is characterized by 
widespread interstitial EMC accumulation. Down-regulation of the miR-17-92 cluster paralleled by 
CTGF and TSP-1 gene up-regulation was confirmed in human idiopathic cardiomyopathy 
specimens. Transfection experiments in aged neonatal rat cardiomyocytes were used to confirm 
CTGF and TSP-1 modulation by miR-18a and 19a/b. Down-regulation of the miR-17-92 cluster has 
also been reported in human IPF lung tissue [48]. 
miR-133, miR-30 and miR-590. Two other major regulators of CTGF expression in cardiac 
fibrosis are miR-133 and miR-30. miR-133 is a cardiac specific miRNA and its expression is 
limited to cardiomyocytes, while miR-30 is expressed in both cardiac fibroblasts and 
cardiomyocytes as well as in other tissues. Duisters et al. [52] reported miR-133- and miR-30c-
mediated repression of CTGF in two animal models of overloaded heart disease: a rat renin-
dependent hypertensive failing heart model (Ren2 rats) and a mouse mechanical stress-induced 
model (mice undergone transverse aortic constriction). They first showed down-regulation of the 
two miRNA families and up-regulation of CTGF in vivo, then confirmed the direct interaction of 
miR-133 and miR-30c with CTGF mRNA in vitro using cultured cardiomyocytes and cardiac 
fibroblasts, and finally proved the functional effects of this interaction on collagen synthesis [52].  
Interestingly, the authors also showed that miR-133 and miR-30c do not exert additive effects on 
CTGF regulation, which might be explained by the overlapping seed regions of these miRs in the 
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3’UTR of the CTGF gene. Similar down-regulation of miR-133 and miR-30c and increased levels 
of CTGF were observed in human hypertrophic heart [52].  
The importance of miR-133 down-regulation in cardiac fibrosis is further supported by the 
findings of Shan and colleagues [82], who investigated the expression of miR-133 in the heart of 
smokers with chronic atrial fibrillation (AF), and in a canine model of nicotine-induced AF. Fibrotic 
structural remodeling was strongly induced by nicotine in both human and canine heart tissue. This 
was associated with an increase in TGF-β1 and the TGF-β pathway downstream targets CTGF and 
collagens both in vivo and in vitro. By in silico analysis, the authors selected miR-133 and miR-590 
as potential regulators of TGF-β1 and TGF-βRII, respectively. miR-133 and miR-590 were strongly 
down-regulated in dog atrial fibroblasts treated with nicotine, and the direct interaction of the two 
miRNAs with their predicted targets could be confirmed by reporter gene assay. miR-30c down-
regulation has also been reported in human IPF lung tissue [48]. 
miR-200. Most data link the five miR-200 family members to EMT [63, 88], thus indicating 
an indirect role in fibrogenesis. Recent data from Wang et al. [63] showed in addition that the miR-
200 family contributes directly to fibrosis by regulation of TGF-β2. Expression of miR-141 and 
miR-200a has been investigated in mouse models of early (ApoE knockout mice injected with 
streptozotocin) and advanced (C57BL6 mice treated with adenine) diabetic nephropathy, as well as 
in rat proximal tubular epithelial cells (NRK52E). Both miRNAs were down-regulated in mice, but 
only miR-200a was sensitive to TGF-β stimulation in NRK52E cells [63]. At the same time, TGF-β 
stimulation induced transformation of NRK52E cells towards a mesenchymal phenotype as 
indicated by reduced E-cadherin expression and increased vimentin and α-SMA expression along 
with enhanced ECM synthesis. In turn, forced up-regulation of both miR-141 and miR-200a in 
NRK52E cells reduced TGF-β2, Smad3 activity and ECM proteins, and also prevented EMT, 
suggesting a miR-200a/TGF-β feedback loop in the pathogenesis of diabetic CKD. In addition, 
reporter gene assays confirmed TGF-β2 as a direct target of miR-141/miR-200a. 
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miR-21. Like the miR-17-92 cluster, miR-21 is traditionally regarded as an oncomir, and due 
to its ubiquitous expression it is one of the most widely investigated miRs [89]. Evidence for an 
important role of miR-21 in fibrosis comes from studies on heart, lung and kidney [66, 65, 67]. 
Thum and colleagues [66] described miR-21 up-regulation in three mouse models of heart failure: 
β1-adrenergic receptor transgenic mice, C57BL/6 mice undergone transverse aortic constriction, and 
C57BL/6 mice treated with isopropanol. In different cell types isolated from failing hearts, miR-21 
was predominantly up-regulated in cardiac fibroblasts, and mediated protection from apoptosis. 
Anti-miR-21 treatment and extracellular signal-regulated kinase/mitogen activated protein kinase 
(ERK/MAPK) blockade induced apoptosis to a similar extent, suggesting a possible regulation of 
ERK/MAPK signaling by miR-21. Accordingly, overexpression of miR-21 in both mouse and rat 
fibroblasts led to increased expression and activation of ERK/MAPK proteins. The authors 
identified sprouty1, a negative regulator of ERK/MAPK, as the direct target of miR-21 mediating 
the effects on this pathway. Nevertheless, more recently, Patrick et al. [90] demonstrated in mir21-/- 
mice, which were exposed to different stimuli resulting in cardiac overload, that miR-21 contributes 
to, but is not essential, for ERK/MAPK activation in  stress-dependent cardiac remodeling. 
Liu et al [65] confirmed the pro-fibrotic activity of miR-21 in human IPF and murine 
bleomycin-induced lung fibrosis. Like in heart failure, miR-21 up-regulation was proportional to the 
severity of lung fibrosis in the animal model. TGF-β1 expression showed the same trend. Therefore, 
the authors elucidated the causal relation between miR-21 and TGF-β1, showing that miR-21 
expression was reduced in TGFβRII dominant negative mice injected with bleomycin. Consistently, 
TGF-β1 treatment of cultured pulmonary fibroblasts induced miR-21 up-regulation and, in turn, 
miR-21 overexpression induced TGF-β1 expression, Smad2 activation, and ECM synthesis. These 
effects were mediated by direct repression of Smad7, the inhibitory Smad which counter-regulates 
Smad2/3 activation. Finally, administration of miR-21 antisense oligonucleotides in vivo attenuated 
bleomycin-induced lung fibrosis. 
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Studies on the role of miR-21 in renal fibrosis further elucidated the interaction of this 
miRNA with TGF-β/Smad signaling [67]. In these experiments, TGF-β-mediated upregulation of 
miR-21 in tubular epithelial cells was prevented by knockdown of Smad3, but not by knockdown of 
Smad2. Consistently, Smad3 deficient mice, but not Smad2 deficient mice, exposed to kidney 
injury by unilateral urethral obstruction were protected from miR-21 up-regulation and fibrosis. 
miR-216, miR-217 and miR-192. miR-216 and miR-217 are two clustered miRNAs encoded 
in the second intron of the RP23 gene. They showed pro-fibrotic effects in murine mesangial cells 
(MCs) [69]. Kato et al. reported upregulation of miR-216/217 in mouse MCs following TGF-β 
treatment, with consequent amplification of TGF-β signaling. miR-216 and miR-217 directly target 
phosphatase and tensin homolog (PTEN), which inhibits the phosphoinositide-3-kinase pathway 
(PI3K), thereby preventing activation of Akt. Thus, down-regulation of PTEN de-represses Akt 
signaling in MCs leading to prolonged cell survival, hypertrophy and increased collagen synthesis. 
In addition, since the promoter region of the RP23 gene contains multiple Smad binding elements 
and E-boxes, the authors could demonstrate that the expression of miR-216 and miR-217 in MCs 
was induced by TGF-β and zinc finger E-box-binding homebox (Zeb) 1 and 2. In turn, Zeb 1 and 2 
are regulated by miR-192 [59]. 
 
MicroRNA regulation of ECM proteins 
miR-29. miR-29 is the best characterized direct regulator of ECM synthesis. Its involvement 
in fibrosis as an anti-fibrotic miRNA has been reported in SSc as well as in other major fibrotic 
disorders. The miR-29 family includes three members: miR-29a/b/c. We could show that all three 
miRNAs are down-regulated in human SSc dermal fibroblasts and SSc skin [47]. miR-29a showed 
the strongest down-regulation in tissues and cells, and the most consistent functional effects on the 
expression of collagen types I and type III. In addition, COL3A1 was validated as a direct target of 
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miR-29a. We also demonstrated that PDGF-B and TGF-β down-regulate miR-29a, and that down-
regulation of miR-29a leads to further upregulation of PDGF-B and TGF-β. This creates a positive 
feed-back loop among profibrotic mechanisms leading to the uncontrolled release of extracellular 
matrix proteins in SSc. Results were confirmed in a bleomycin-induced mouse model of skin 
fibrosis, in which the tyrosine-kinase inhibitor imatinib mesylate was able to restore miR-29a 
levels. 
In murine and human hearts, down-regulation of the miR-29 family following myocardial 
infarction has been reported [72]. Van Rooji et al. showed that cardiac fibroblasts, but not 
cardiomyocytes, are responsible for the effects of miR-29 on ECM synthesis in myocardial 
infarction. They hypothesized that miR-29 down-regulation is mediated by TGF-β following 
cardiac injury, and that this axis is controlled by the parallel induction of brain natriuretic peptide 
(BNP), which causes repression of TGF-β. COL1A1, COL1A2, COL3A1, FBN1, and ELN1 genes 
were validated as direct miR-29 targets. In addition, miR-29b knockdown with cholesterol-
conjugated antagomirs in C57BL/6 male mice induced COL1A1, COL1A2, and COL3A1 mRNA 
overexpression in cardiac tissue.  
A clear anti-fibrotic function of the miR-29 family was also shown in hypertensive kidney 
disease [74]. Liu et al. found that miR-29b was overexpressed in a mouse model, which is protected 
against salt-induced hypertensive renal medullary fibrosis (SS-13BN) after high-salt diet. Silencing 
of miR-29b in the kidney of these animals caused up-regulation of a large number of ECM and 
ECM-modulating genes, subsequently validated as direct targets of miR-29b by reporter gene assay 
(COL1A1, COL3A1, COL4A1, COL5A1, COL5A2, COL5A3, COL7A1, COL8A1, MMP2, and 
ITGB1). As reported by Du et al [75], miR-29a down-regulation can also be induced in vitro in 
human proximal tubular epithelial cells (HK-2 cells) by high glucose and TGF-β stimulation, with 
similar effects on the expression of multiple collagen genes, suggesting a role for miR-29 also in 
diabetic nephropathy. 
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Regarding lung fibrosis, down-regulation of miR-29 has been reported by Cushing et al. [73] 
in bleomycin-treated mice, which was paralleled by an increase in COL3A1 and COL4A1 
expression. In addition, the same authors investigated the effects of silencing of miR-29 family 
members in human fetal lung fibroblasts. They identified new direct targets, among them both 
structural ECM genes and enzymes involved in tissue remodeling, namely NID1, ITGA11, 
ADAMTS9, and ADAMTS12. In lungs as well as in the skin, heart and kidney, TGF-β was able to 
reduce miR-29 levels. 
Lastly, miR-29 down-regulation (miR-29c) has been reported in a mouse model of non-
alcoholic steatohepatitis [57], although functional investigations of miR-29 in the liver are still 
lacking. 
Other miRNAs. Additional miRNAs have been shown to regulate ECM synthesis in the 
kidney: miR-377 and miR-449. Wang et al. [79] showed pro-fibrotic effects of miR-377 in human 
mesangial cells following high glucose and TGF-β administration and in animal models of type I 
diabetes. These effects were mediated by an indirect upregulation of fibronectin via targeting the 
fibronectin inhibitors p21-activated kinase and superoxide dismutase, Muth et al. [81] demonstrated 
that the expression of miR-449a/b was reduced in human fibroblasts cultured under hypoxic 
conditions and in human kidney transplants displaying chronic allograft nephropathy. miR-449 
down-regulation induced Serpine-1 (PAI-1) expression. Serpine-1 inhibits tissue-type (tPA) and 
urokinase-type plasminogen activator (uPA), which mediate proteolysis of ECM proteins and 
activation of latent metalloproteinases (MMPs). Thus, the authors hypothesized that miR-449 
down-regulation promotes ECM accumulation in hypoxic fibroblasts and chronic post-transplant 
allograft remodeling in the kidney.   
 
Conclusions and perspectives 
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Our review outlines the potentially important role of miRNAs in fibrosis. With some 
exceptions, most of the miRNAs reported in this review are ubiquitously expressed, indicating that 
the majority of pro- or anti-fibrotic miRNAs might be common regulators of fibrosis in different 
organs and disease settings. In addition, several key pro-fibrotic molecules are regulated by multiple 
miRNAs [51, 52, 58, 62, 65-67, 69, 82, 83].  
The partially redundant interaction between miRNAs and their targets might hamper the use of 
miRNA mimics or inhibitors as potential therapeutic tools. However, data on the use of antagomirs 
in animal models show promising results [72, 65, 90]. It is important for the development of 
targeted therapies that miRNAs exert rather mild to moderate effects on single molecules, but that 
these effects are additive when multiple molecules of a certain pathophysiological pathway are 
regulated. Therefore, miRNAs are of particular interest for targeted therapies in fibrosis, when they 
regulate multiple rate limiting molecules of profibrotic pathways. In addition, since differentially 
expressed miRNAs are often disease specific and do not play major roles under normal conditions 
in adult tissue/or in quiescent cells, targeting of an aberrantly expressed miRNA is expected to be 
well tolerated [91]. Indeed, many miRNA knockout animal models do not display a specific 
phenotype unless they are challenged with a stimulus causing cellular stress in target organs [66]. 
However, the miRNA machinery in fibrosis is still far from being fully elucidated, although 
research in this field in the last years has been considerably fostered. 
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Figure legend 
Figure 1. Schematic miRNA biogenesis and regulation. The miRNA gene is transcribed (pri-
miRNA) and cut in the nucleus to generate pre-miRNA. Pre-miRNA is transported to the cytoplasm 
and is further processed there. Mature miRNA is originated as a mature miRNA:miRNA* 
(passenger strand) duplex. Mature miRNA is incorporated in RISC to bind a target mRNA. Perfect 
miRNA-mRNA binding leads to mRNA cleavage, while imperfect miRNA-mRNA binding leads to 
translational repression (rarely to translational stimulation). Levels of cellular bioactive miRNA can 
be controlled by both transcriptional regulation, including epigenetic modifications and target-
dependent loops, and post-transcriptional regulation, including decoy mechanisms exerted by 
pseudogenes, and intercellular exosome-dependent trafficking. 
DNMTs = DNA methyltransferases; HDACs = histone deacetylases; DGCR8 = DiGeorge 
syndrome critical region 8; RISC = RNA-induced silencing complex; ψ = pseudogene. 
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Table 1. Examples of primary (idiopathic) and secondary fibrotic disorders with 
multiple/single organ presentation 
Primary Secondary 
Systemic 
Systemic sclerosis Graft versus host disease 
 Drug-induced  
Nephrogenic systemic fibrosis 
Sarcoidosis Secondary amyloidosis 
Amyloidosis Post-radiation 
 Toxic environmental exposure 
 Storage disorders (hemochromatosis, 
glycogenosis, Gaucher’s disease, etc) 
Lungs 
Idiopathic pulmonary fibrosis Pneumoconiosis 
Histiocytosis X Infectious pneumonitis 
Cryptogenic organizing pneumonia Tuberculosis 
 Hypersensitive pneumonitis 
 Inherited disorders 
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 Autoimmune diseases 
 Transplant rejection 
 Drug-induced 
 Post-radiation 
 Sarcoidosis 
 Amyloidosis 
Heart 
Idiopathic restrictive cardiomyopathy Coronary artery disease/myocardial infarction 
 Pressure-overload heart (long standing arterial 
hypertension, valvular disease) 
 Infectious myocarditis 
 Autoimmune diseases 
 Transplant rejection 
 Familial hypertrophic cardiomyopathy 
 Arrhythmogenic right ventricular 
cardiomyopathy 
 Drug-induced 
 Post-radiation 
 Sarcoidosis 
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 Amyloidosis 
Kidney 
Idiopathic nephrotic syndrome Diabetic glomerulosclerosis 
Idiopathic membranoproliferative 
glomerulonephritis 
Hypertensive nephrosclerosis 
 Autoimmune glomerular diseases 
 Drug-induced 
 Post-radiation 
 Amyloidosis 
 Transplant rejection 
Liver 
Primary biliary cirrhosis Chronic viral hepatitis 
Primary sclerosing cholangitis Schistosomiasis 
 Alcoholic liver disease  
 Nonalcoholic fatty liver disease 
 Drug-induced 
 Toxics environmental exposure 
 Inherited metabolic disorders 
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 Autoimmune hepatitis 
 Intestinal bypass 
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Table 2. Major molecular mediators elevated in fibrotic disorders 
Cytokines 
Transforming growth factor-β (TGF-β) 
Interleukin (IL)-4 
IL-13 
IL-17 
Chemokines 
CCL2 
CXCL8 
CXCL12 
Growth factors 
Connective tissue growth factor (CTGF) 
Platelet-derived growth factor (PDGF) 
Vascular endothelial growth factors (VEGF) 
Fibroblast growth factor (FGF) 
Insulin-like growth factor-1 (IGF-1) 
 
Small secreted signaling proteins 
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Wnt proteins 
Endothelin-1 (ET-1) 
 
SSc = systemic sclerosis; LC = liver cirrhosis; CF = cardiac fibrosis; CKD = chronic kidney 
disease; IPF = idiopathic pulmonary fibrosis. 
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Table 3. MicroRNAs linked to fibrosis  
MicroRNA Effect Organ  Predicted target 
and confirmation 
level 
Putative role in 
fibrosis 
Reference 
let-7d Anti-
fibrotic 
Lung Reporter gene 
assay (HMGA2) 
↓EMT 48 
miR-107 Anti-
fibrotic 
Kidney -  ↓ Interstitial 
fibrosis in 
allograft 
transplant 
49 
miR-132 Anti-
fibrotic 
Heart, liver Target mRNA 
changes in 
mimic/silencing 
miRNA 
transfection 
(RAS-GTPase, 
MeCP2) 
↑angiogenesis 
and 
↓myofibroblasts 
differentiation 
50, 51 
miR-133 Anti-
fibrotic 
Heart Reporter gene 
assay (CTGF, 
TGF-β1) 
↓ TGF-β 
signaling and 
↓CTGF signaling 
52, 82 
miR-141 Anti-
fibrotic 
Kidney  ↓TGF-β  
and ↓TGF-β 
dependent EMT 
62 
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miR-142-3p Pro-fibrotic Kidney  Interstitial 
fibrosis in 
allograft 
transplant  
49 
miR-15b, 
miR-16 
Anti-
fibrotic 
Liver, lung Reporter gene 
assay (Bcl-2) 
↑apoptosis 53, 54 
miR-150 Anti-
fibrotic 
Liver Target protein 
changes in 
mimic/silencing 
miRNA 
transfection (c-
myb) 
↓activation and 
proliferation in 
HSC 
55 
miR-155 Pro-fibrotic Lung, liver Reporter gene 
assay (KGF-FGF-
7); target protein 
changes in 
mimic/silencing 
miRNA 
transfection 
↓mesenchymal-
epithelial cross-
talk  
56, 57 
miR-17-92 
cluster (miR-
18a, 19a/b) 
Anti-
fibrotic 
Liver, heart, 
lung 
Target protein 
changes in 
mimic/silencing 
miRNA 
transfection 
↓CTGF  
and ↓ TSP-1 
58, 83, 48 
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(CTGF; CTGF 
and TSP-1) 
miR-192 Pro-fibrotic Kidney  Reporter gene 
assay (ZEB1/2) 
↑collagen 
synthesis and 
↑EMT 
59, 68 
miR-194 
(clustered with 
miR-215) 
Anti-
fibrotic 
Liver Target protein 
changes in 
mimic/silencing 
miRNA 
transfection (rac1) 
↓activation and ↓ 
proliferation in 
HSC 
55 
miR-199a/b Pro-fibrotic Heart, Liver  Reporter gene 
assay (Dyrk1); 
↑ECM synthesis 
via 
calcineurin/NFAT 
signaling 
60, 61 
miR-200 
family 
(miR-200a/b) 
Anti-
fibrotic 
Kidney, 
liver 
Reporter gene 
assay (TGFβ2 for 
miR-200a, 
ZEB1/2 for miR-
200b); target 
mRNA changes in 
mimic/silencing 
miRNA 
transfection 
↓TGF-β signaling 
and ↓ TGF-β -
dependent EMT 
62, 63, 57 
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miR-204 Anti-
fibrotic 
Kidney  Interstitial 
fibrosis in 
allograft 
transplant  
49 
miR-208 Pro-fibrotic Heart Reporter gene 
assay (THRAP1 
and myostatin) 
↓mycocardial 
contractility and 
↑fibrosis by 
derepression of 
negative 
regulators of 
stress-response 
genes  
64 
miR-21 Pro-fibrotic Lung, heart, 
kidney 
Reporter gene 
assay (Smad7 in 
lung); in vivo 
functional assay 
(Spry1 in heart); 
in vitro functional 
assay for Smad 
interactions 
↑TGF-β canonical 
(via Smad7 de-
repression of 
Smad2/3) and non 
canonical 
signaling (via 
Spry1 
derepression of 
ERK/MAPK) 
65, 66, 67 
miR-211 Anti-
fibrotic 
Kidney Real time PCR 
confirmation of 
Interstitial 
fibrosis in 
allograft 
49 
37 
 
miRNA  transplant 
 
miR-215 Pro-fibrotic Kidney  Reporter gene 
assay (ZEB1/2) 
↑EMT 68 
miR-216, 
miR-217 
Pro-fibrotic Kidney Reporter gene 
assay (PTEN) 
↑Akt signaling 
via PTEN 
derepression 
69 
miR-23a 
(clustered with 
miR-27a) 
Pro-fibrotic Lung Systems biology 
approach and real 
time PCR (ZEB1) 
↑EMT 70 
miR-26a/b Anti-
fibrotic 
Lung Microarray - if there is no 
functional assay, 
how do you know 
it is antifibrotic? 
48 
miR-27b, 
miR-27a 
Pro-fibrotic Liver Reporter gene 
assay (RXR-α) 
↑lipid 
accumulation and 
proliferation of 
HSC 
71 
miR-29a/b/c Anti-
fibrotic 
SSc, heart, 
lung, 
kidney, 
liver 
Reporter gene 
assays (different 
collagens, FBN1, 
ELN1, MMP2, 
ITGB1; target 
Directly ↓ECM 
synthesis 
47, 72, 73, 
48, 74, 75, 
57 
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mRNA changes in 
mimic/silencing 
miRNA 
transfection 
miR-30c Anti-
fibrotic 
Heart, lung Reporter gene 
assay (CTGF) 
↓CTGF signaling 51, 48 
miR-32 Pro-fibrotic Kidney Real time PCR 
confirmation of 
miRNA  
Interstitial 
fibrosis in 
allograft 
transplant  
49 
miR-335 Anti-
fibrotic 
Liver Target mRNA 
changes in 
mimic/silencing 
miRNA 
transfection 
(TNC) 
↓HSC activation 
and migration 
76 
miR-338* Pro-fibrotic Lung Reporter gene 
assay (LPA1) 
↑fibroblast 
proliferation 
77 
miR-34a Pro-fibrotic Liver Reporter gene 
assay (ACSL1) 
↑lipids 
biosynthesis 
78, 57 
miR-377 
(clustered with 
miR-382) 
Pro-fibrotic Kidney Reporter gene 
assay (PAK1, 
SOD) 
↑fibronectin 
synthesis 
79 
39 
 
miR-382 Pro-fibrotic Kidney Reporter gene 
assay (SOD2) 
↑EMT mediated 
by ↓ protection 
against 
mithocondrial 
oxidative stress 
 
80 
miR-449a/b Anti-
fibrotic 
Kidney Target mRNA 
changes in 
mimic/silencing 
miRNA 
transfection 
(SERPINE1) 
↑ECM synthesis 
in hypoxic 
conditions via 
downregulation 
of miR-449 
 
81 
 miR-590 Anti-
fibrotic 
Heart Reporter gene 
assay (TGFβR2) 
↓TGF-β signaling 82 
 
EMT = epithelial-to-mesenchymal transition; HMGA2 = high mobility group AT-hook 2; RAS-
GTPase = Rat sarcoma guanosine triphosphatase; MeCP2 = methylCpG binding protein 2; CTGF = 
connective tissue growth factor; TGF-β = transforming growth factor- β; Bcl-2 = B-cell lymphoma 
2; HSC = hepatic stellate cell; c-myb = avian myeloblastosis proto-oncoprotein; KGF = 
keratinocytes growth factor; ZEB = zinc finger E-box-binding homebox; rac1 = Ras-related C3 
botulinum toxin substrate 1; Dyrk1 = dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 
1a; NFAT = nuclear factor of activated T-cells; βMHC = β myosin heavy chain; Smad = small 
mother against decapentaplegic; Spry1 = protein sprouty homolog 1; ERK = extracellular signal-
regulated kinase; MAPK = mitogen activated protein kinase; PTEN = phosphatase and tensin 
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homolog; Akt = non-specific serine/threonine-protein kinase; RXR-α = retinoid X receptor-α; 
FBN1 = fibrillin1; ELN1 = elastin1; MMP2 = metalloproteinase  2; ITGB1 = integrin β1; TNC = 
tenascin; LPA1 = lipophosphatidic acid; ACSL1 = Long-chain-fatty-acid-CoA ligase 1; PAK1 = 
p21 activated kinase 1; SOD = superoxide dismutase;  TGF-β receptor 2 = transforming growth 
factor-β receptor type 2; TSP-1 = thrombospondin-1. 
 
 
 
 
 
